Experienced in Hypertension

Gerard T. Wilkins

Dunedin, OTA, NZ 
Experienced in Hypertension
Dunedin, OTA, NZ 
OverviewLocationsClinical Research

Overview

Gerard Wilkins practices in Dunedin, New Zealand. Mr. Wilkins is rated as an Experienced expert by MediFind in the treatment of Hypertension. His top areas of expertise are Hypertension, Type 2 Diabetes (T2D), Heart Failure, and Cardiomyopathy.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Hypertension.

Gender
Male

Locations

Dunedin, OTA, New Zealand
Other Locations
OTA, New Zealand

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Evaluation of a Sirolimus Eluting Bioadaptor as Compared to a Zotarolimus Eluting Stent in De Novo Native Coronary Arteries ELX-CL-1805
Evaluation of a Sirolimus Eluting Bioadaptor as Compared to a Zotarolimus Eluting Stent in De Novo Native Coronary Arteries ELX-CL-1805
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Ferric Carboxymaltose
Study Phase: Phase 3
Evaluation of a Thin Strut Metallic Coronary Device: the Elixir DynamXTM Sirolimus Eluting Coronary Bioadaptor System
Evaluation of a Thin Strut Metallic Coronary Device: the Elixir DynamXTM Sirolimus Eluting Coronary Bioadaptor System
Enrollment Status: Completed
Publish Date: April 26, 2021
Intervention Type: Device
Study Phase: Not Applicable
View 2 Less Clinical Trials

35 Total Publications

Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus.
Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus.
Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
Published: July 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wilkins's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile